Recent efforts by the US Food and Drug Administration to regulate a type of personalized medicine are “unprecedented and unlawful,” a coalition of manufacturers and clinicians claim in a recent Citizen’s Petition.
Law firm Hyman, Phelps & McNamara filed the 9 January petition with the FDA on behalf of the Coalition to Preserve Access to Pharmacogenomics (PGx). In it, the group argues...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?